



RHEUMATOLOGY

Şule Ketenci Ertaş, MD

Rheumatology Department · Acibadem Healthcare Group

MEDICALLY VERIFIED PROFILE

EXPERIENCE
7+ yearsLANGUAGES
Turkish · EnglishCONSULTS
Video · On-sitePATIENTS
90+ countriesSPECIALTY
RheumatologyFOCUS
Autoimmune rheumatic
diseases · ...HOSPITAL
Acibadem Healthcare
GroupDEPARTMENT
Rheumatology Department

CLINICAL FOCUS

Şule Ketenci Ertaş, MD is a Rheumatology specialist at Acibadem in Turkey. Areas of focus include Array. International patients can request a free consultation or a second medical opinion.

Şule Ketenci Ertaş, MD is a rheumatologist with 7 years of experience. Her listed areas of expertise include IgG4-related disease, Behçet disease, autoimmune rheumatic diseases, musculoskeletal conditions, IgG4-related tubulointerstitial nephritis, and rituximab therapy for IgG4-related disease.

Autoimmune rheumatic diseases

Musculoskeletal conditions

Behçet disease

IgG4-related disease

IgG4-related tubulointerstitial nephritis



CONDITIONS TREATED

Polymyalgia rheumatica

Musculoskeletal conditions

Behçet disease

Igg4-related disease

Igg4-related tubulointerstitial nephritis



EDUCATION & TRAINING

- 2019 Erciyes University Faculty of Medicine Rheumatology
- 2014 Erciyes University Faculty of Medicine Internal Medicine
- 2007 Hacettepe University Faculty of Medicine



PROFESSIONAL EXPERIENCE

- 2021 Acibadem Health Group
- 2020–2021 Kayseri City Hospital, Rheumatology Specialist Dr.
- 2019–2020 Tokat State Hospital, Rheumatology Specialist Dr.



PROCEDURES PERFORMED

Rituximab therapy for igg4-related disease

Systemic lupus erythematosus treatment

ACIBADEM HEALTHCARE GROUP Verified
network figures

45+

HOSPITALS & CLINICS

7

JCI-ACCREDITED

90+

COUNTRIES SERVED

20+

LANGUAGES IN-HOUSE



MEMBERSHIPS

- Turkish Rheumatology Association



SELECTED PUBLICATIONS

- A case of fulminant demyelinating disease associated with golimumab treatment (2020) Yetkin, M.
- Fatigue Is Common and Predicted by Female Gender and Sleep Disturbance in Patients with Chronic Spontaneous Urticaria...
- Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU Allergy,...

10 publications listed on the online profile

PHONE
+90 535 876 04 89
Tap to callWHATSAPP
+90 536 904 82 62
Tap to chatWEBSITE
acibademinternational.com
Open the siteFREE CONSULTATION
Ask Dr. Ertaş about your case
Reply within 24 hours